Zepbound Maker Eli Lilly Forecasts Strong Profits Amid Rollout Of Weight Loss Drug

Eli Lilly shares jumped in premarket Tuesday after the company reported better-than-expected fourth quarter results and revised its 2024 forecast ahead of expectations, amid soaring demand for its diabetes drug Mounjaro and newly-approved weight loss drug Zepbound.Eli Lilly reported global revenues of $9.35 billion during the last three months of 2023, an increase of nearly 30% from the same period the year before. This was buoyed by strong sales and higher prices of Mounjaro, the company’s blockbuster dia ...